Consistent rates of kill of Staphylococcus aureus by gentamicin over a 6-fold clinical concentration range in an in vitro pharmacodynamic model (IVPDM)

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 1, 2006, Pages 108-111

  Schafer, Jeremy A ^a   Hovde, Laurie B ^a   Rotschafer, John C ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Adjunctive aminoglycosides; Pharmacodynamics; S. aureus; Single daily dose

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; GENTAMICIN; SODIUM CHLORIDE;

ANALYSIS OF VARIANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERICIDAL ACTIVITY; COLONY FORMING UNIT; CONTROLLED STUDY; DILUTION; DRUG HALF LIFE; IN VITRO STUDY; INOCULATION; MINIMUM INHIBITORY CONCENTRATION; MODEL; NONHUMAN; PHARMACODYNAMICS; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, BACTERIAL; GENTAMICINS; MICROBIAL SENSITIVITY TESTS; STAPHYLOCOCCUS AUREUS;

EID: 33748052027     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl216     Document Type: Article

References (24)

1. Pfaller MA, Jones RN, Doern GV et al. Bacterial pathogens isolated from patients with bloodstream infection: Frequencies of occurrence and antimicrobial susceptibility patterns from the SENTRY antimicrobial surveillance program (United States and Canada, 1997). Antimicrob Agents Chemother 1998; 42: 1762-70.
2. Crossley KB, Archer GL. The Staphylococci in Human Disease. New York: Churchill Living Stone Inc., 1997.
3. Crouch M. Infective endocarditis. In: Dipiro JT, ed. Pharmacotherapy a Pathophysiologic Approach, 5th edition. New York: McGraw-Hill, 2002; 1905.
4. Moore RD, Lietman PS, Smith CR. Clinical response to aminoglycoside therapy: Importance of the ratio of peak concentration to minimal inhibitory concentration. J Infect Dis 1987; 155: 93-9.
5. Ross GH, Hovde LB, Ibrahim YH et al. In vitro pharmacodynamic analysis of single daily dosing versus conventional dosing of gentamicin administered with penicillin against Enterococcus faecalis. Pharmacotherapy 2001; 21: 1479-85.
6. Micromedex. Drug Dex Evaluation of Gentamicin. www.micromedex.com (31 August 2005, date last accessed).
7. Zabinski RA, Vance-Bryan K, Krinke AJ et al. Elimination of the activity of temafloxacin versus Bacteroides fragilis using an in vitro pharmacodynamic system. Antimicrob Agents Chemother 1993; 37: 1377-9.
8. EUCAST Online Database. Antimicrobial Wildtype Distribution of Microorganisms. www.escmid.org (30 January 2006, date last accessed).
9. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Third Edition: Approved Standard. NCCLS, Villanova, PA, USA, 1993.
10. Soriano F, Santamaria M, Ponte C et al. In vivo significance of the inoculum effect of antibiotics on Escherichia coli. Eur J Clin Microbiol Infect Dis 1988; 7: 410-2.
11. Bourget P, Fernandez H, Delouis C et al. Pharmacokinetics of tobramycin in pregnant women. Safety and efficacy of a once-daily dose regimen. J Clin Pharm Ther 1991; 16: 167-76.
12. Calandra T, Zinner SH, Viscoli C et al. Efficacy and toxicity of single daily doses of amikacin and ceftriaxone versus multiple daily doses of amikacin and ceftazidime for infection in patients with cancer and granulocytopenia. Ann Intern Med 1993; 119: 584-93.
13. Dudley MN, Zinner SH. Single daily dosing of amikacin in an in-vitro model. J Antimicrob Chemother 1991; 27: 15-19.
14. Gilbert DN, Lee BL, Dworkin RJ et al. A randomized comparison of the safety and efficacy of once-daily gentamicin or thrice-daily gentamicin in combination with ticarcillin-clavulanate. Am J Med 1998; 105: 182-91.
15. Kafetzis DA, Sianidou L, Vlachos E et al. Clinical and pharmacokinetic study of a single daily dose of amikacin in paediatric patients with severe Gram-negative infections. J Antimicrob Chemother 1991; 27: 105-12.
16. Karachalios GN, Houpas P, Tziviskou E et al. Prospective randomized study of once-daily versus twice-daily amikacin regimens in patients with systemic infections. Int J Clin Pharmacol Ther 1998; 36: 561-4.
17. Maller R, Ahrne H, Holman C et al. Once versus twice-daily amikacin regimen: Efficacy and safety in systemic gram-negative infections. J Antimicrob Chemother 1993; 31: 939-48.
18. Murry KR, McKinnon PS, Mitrzyk B et al. Pharmacodynamic characterization of nephrotoxicity associated with once-daily aminoglycoside. Pharmacotherapy 1999; 19: 1252-60.
19. Nicolau, DP, Freeman CD, Belliveau PP et al. Experience with a once-daily aminoglycoside program administered to 2184 adult patients. Antimicrob Agents Chemother 1995; 39: 650-5.
20. Prins JM, Buller HR, Kuijper EJ et al. Once versus thrice daily gentamicin in patients with serious infections. Lancet 1993; 341: 335-9.
21. Rybak MJ, Abate BJ, Kang SL et al. Prospective evaluation of the effect of an aminoglycoside dosing regimen on rates of observed nephrotoxicity and ototoxicity. Antimicrob Agents Chemother 1999; 43: 1549-55.
22. Bakri FE, Pallett A, Smith AG et al. Ototoxicity induced by once-daily gentamicin. Lancet North Am Ed 1998; 351: 1407-8.
23. Koo J, Tight R, Rajkumar V et al. Comparison of once-daily versus pharmacokinetic dosing of aminoglycosides in elderly patients. Am J Med 1996; 101: 177-83.
24. Bisno AL, Dismukes WE, Durack DT et al. Antimicrobial treatment of infective endocarditis due to viridans streptococci, entercocci, and staphylococci. JAMA 1989; 261: 1471-7.